SEC Form 8-K filed by AIM ImmunoTech Inc.
$AIM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
10-Q - AIM ImmunoTech Inc. (0000946644) (Filer)
NT 10-Q - AIM ImmunoTech Inc. (0000946644) (Filer)
424B5 - AIM ImmunoTech Inc. (0000946644) (Filer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
Maxim Group resumed coverage of AIM ImmunoTech with a rating of Buy and set a new price target of $2.00
OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing Ampligen (rintatolimod), which was presented at the 40th Annual SITC Meeting on November 7, 2025, at National Harbor, MD. Platinum-sensitive patients with measurable peritoneal disease were eligible for combination therapy with up to six treatment cycles at 3-week intervals of intraperitoneal cisplatin, intravenous pembrolizumab (also known as Merck's Keytruda) and intraperitoneal Ampligen. Of the 27 patients included in the trial, 24 were evaluable for r
OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen® (rintatolimod) was accepted in a late-breaking abstract at the 40th Annual SITC Meeting being held November 5-9, 2025 at National Harbor, MD. Details of the poster presentation are as follows: Title: A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical OutcomesPresenting Author: Mackenzy M. Radolec, MD, Clinical Assistant Professo
OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the European Patent Office has officially granted AIM's European Patent No. 4,096,675, titled "Compositions for Treating LONG COVID," covering compositions of matter of AIM's proprietary dsRNAs including, for example, Ampligen® (rintatolimod) for use in the treatment of Long COVID. "While AIM's immediate and primary focus is to build upon the continued positive results from our late-stage pancreatic cancer clinical program, this new European patent in Long COVID strengthens our intellectual property portfolio while providing additional validation of our belief in Amp
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Company's Board of Directors (the "Board") has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately. Mr. Chemerow brings more than 40 years of finance, accounting and operations leadership experience across multiple industries. He previously served as the Chief Financial Officer and Treasurer, and prior to that as Chief Revenue Officer, of Comscore, Inc., an American-based global media measurement and analytics company. Prior to his tenure at Comscore, Mr. Chemerow served as the Chief Operating Officer an
Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders In AIM's View, the Activist Group's Plan to Reimburse Individuals More Than $5 Million for Failed Attempts to Gain Control of the Board – Without Putting this to a Shareholder Vote – Is Grossly Irresponsible and Not in the Best Interests of All Shareholders Reminds Shareholders that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Recommended Against Giving the Dissident Nominees Control of the AIM Board, Specifically Citing Their Lack of a Plan, Amo
Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Elected Kellner Group Reiterates Plan to Revitalize AIM, Accelerate Clinical Development and Restore Value for StockholdersKellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we" or "us" and, as nominees, t
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by collaborators AstraZeneca (pancreatic cancer) and Merck (advanced ovarian cancer) Company to host conference call and webcast on Tuesday, April 1st at 8:30 AM ET OCALA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the fourth quarter and full year 2024 and provided a business
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with positive clinical trial data, underscoring big pharma collaboration and commercialization opportunities – Company to host conference call and webcast today, November 15th, at 8:30 AM ET OCALA, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") has reported its financial results for the third quarter 2024. As previously announced, the Company will host a conference call and webcast today, November 15, 2024 at 8:30 AM ET (details below). AIM Chief Execu
OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), announced today that management will host a conference call and webcast to discuss the Company's Q3 2024 operational and financial results on Friday, November 15, 2024 at 8:30 AM ET. The call will be hosted by members of AIM's leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Invest
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13G - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)